Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Does Subacromial Injection With Glutamate Receptor (NMDAR) Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02967640

Organisation Name: Helse Møre og Romsdal HF

Overal Status: Recruiting

Start Date: May 1, 2018

Last Update: January 27, 2020

Lead Sponsor: Helse Møre og Romsdal HF

Brief Summary: The hypothesis of the present study is that in patients with rotator cuff tendinopathy a specific pharmacological blocking of peripheral glutamate-receptor N-methyl-d-aspartate receptor type1 (NMDAR) glutamate receptors will result in pain alleviation. Activated NMDAR1 has been demonstrated to be crucial for pain regulation in various pain disorders, and in biopsies from patients with tendinopathy, NMDAR1 was found to be activated.

To test this hypothesis a specific NMDA receptor antagonist, ketalar (ketamine), will be injected guided by ultrasound into the subacromial space in patients with rotator cuff tendinopathy, and subsequently the pain response will be assessed.

Conditions:
  • Rotator Cuff Tendinitis
  • Chronic Pain


Total execution time in seconds: 0.23167300224304